| Business Summary | | Questcor
Pharmaceuticals
Inc.
is
an
integrated
specialty
pharmaceutical
company
focused
on
the
development,
acquisition
and
marketing
of
acute
care
and
critical
care
hospital/specialty
pharmaceutical
products.
The
Company
currently
markets
three
products
in
the
US:
Glofil-125
and
Inulin
in
Sodium
Chloride,
which
are
both
injectable
agents
that
assess
kidney
function
by
measuring
glomerular
filtration
rate;
and
Ethamolin,
an
injectable
drug
used
to
treat
esophageal
varices
that
have
recently
bled.
Additionally,
the
Company
earns
royalties
from
its
strategic
partner,
Crinos
Industria
Farmacobiologica
SpA
on
sales,
in
Italy,
of
Pramidin,
an
intranasal
form
of
metoclopramide
for
the
treatment
of
various
gastrointestinal
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Questcor
Pharmaceuticals
is
an
integrated
specialty
pharmaceutical
company
focused
on
the
development,
acquisition
and
marketing
of
acute
care
and
critical
care
hospitality/specialty
pharmaceutical
products.
For
the
six
months
ended
6/30/01,
revenues
rose
65%
to
$2
million.
Net
loss
fell
57%
to
$3.9
million.
Revenues
reflect
an
increase
in
product
sales
of
Ethamolin,
Glofil,
and
Inulin.
Lower
loss
also
reflects
lower
development
expenses
for
Emitasol. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Charles Casamento, 55 Chairman,
Pres and CEO | $402K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|